These findings suggest that co-treatment with ADA and GDC increases BC cells sensitivity to GDC and that substantial tumor inhibition may be obtained with moderate dosages of both drugs, hence decreasing the risks associated with GDC-0941. The gene discussed is SLC25A16; the disease is neoplasm.